What Is Methotrexate?
Methotrexate is a dihydrofolate reductase inhibitor and antimetabolite that suppresses immune responses and has anti-inflammatory properties. It is a cornerstone DMARD for rheumatoid arthritis.
Methotrexate inhibits dihydrofolate reductase, blocking folate-dependent nucleotide synthesis. At low doses used for RA, it accumulates in inflammatory cells and inhibits polyamine and aminoimidazole carboxamide ribonucleotide (AICAR) transformylase, resulting in adenosine accumulation and anti-inflammatory effects.
Indications
- Rheumatoid arthritis (first-line DMARD)
- Psoriasis and psoriatic arthritis
- Polyarticular juvenile idiopathic arthritis
- Ankylosing spondylitis (off-label)
- Systemic lupus erythematosus (off-label)
- Acute leukemia, lymphoma, osteosarcoma
- Ectopic pregnancy (medical management)
Dosage and Administration
CRITICAL: METHOTREXATE IS DOSED WEEKLY, NOT DAILY
Rheumatoid Arthritis:
- Initial: 7.5 mg once weekly
- Increase by 2.5 mg every 4-8 weeks
- Maintenance: 15-25 mg once weekly
- Maximum: 25 mg weekly (rarely exceeded)
Route Options:
- Oral tablets: taken as single weekly dose or divided into 3 doses over 12 hours on one day/week
- Subcutaneous/IM injection: preferred for better bioavailability, used if oral GI intolerance
- Intrathecal: only for CNS malignancies (specialized administration)
Folic Acid Supplementation (MANDATORY):
- 1 mg daily on days NOT taking methotrexate
- OR 5 mg once weekly (taken 24 hours after methotrexate)
- Reduces toxicity and GI side effects
FATAL if given daily by mistake instead of weekly. All prescriptions and patient education must emphasize WEEKLY dosing. Baseline CBC, liver function tests, and renal function essential. Monthly monitoring required initially, then every 8-12 weeks once stable.